Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

(2021) Corrado Pelaia et al.   Journal of Asthma and Allergy

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

(2021) Santi Nolasco et al.   Journal of Allergy and Clinical Immunology-In Practice

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

(2021) Andrew Menzies-Gow et al.   Lancet Respiratory Medicine

Comparability of asthma control test scores between self and physician-administered test

(2020) Claudia Crimi et al.   RESPIRATORY MEDICINE

Real-life experience with benralizumab during 6 months

(2020) A. Padilla-Galo et al.   BMC Pulmonary Medicine

Long-term therapy response to anti-interleukin-5 biologics in severe asthma – a real-life evaluation

(2020) Katrien Eger et al.   Journal of Allergy and Clinical Immunology-In Practice

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities

(2020) Claudia Crimi et al.   World Allergy Organization Journal

Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study

(2019) Luis A. Pérez de Llano et al.   Journal of Allergy and Clinical Immunology-In Practice

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

(2019) Kenneth R. Chapman et al.   ALLERGY

Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline

(2019) Fernando Holguin et al.   EUROPEAN RESPIRATORY JOURNAL

Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose

(2019) Corrado Pelaia et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

(2018) Bradley E. Chipps et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Economic impact of severe asthma in Spain: multicentre observational longitudinal study

(2018) Carlos Melero et al.   JOURNAL OF ASTHMA

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe and Difficult-to-Treat Asthma in Adults

(2017) Elliot Israel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis

(2017) Ian D. Pavord et al.   npj Primary Care Respiratory Medicine

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

(2016) A. Magnan et al.   ALLERGY

Current concepts of severe asthma

(2016) Anuradha Ray et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care

(2015) Merritt L. Fajt et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Enhanced innate type 2 immune response in peripheral blood from patients with asthma

(2014) Kathleen R. Bartemes et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations

(2009) Helen K. Reddel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE